Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Health»Thermo Fisher Scientific expands its SARS-CoV-2 testing portfolio in India with a point-of-care testing platform
    Health

    Thermo Fisher Scientific expands its SARS-CoV-2 testing portfolio in India with a point-of-care testing platform

    By June 15, 2021No Comments3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    The Accula System is an innovative platform that will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.

    Mumbai (Maharashtra) [India], June 15: Thermo Fisher Scientific today announced the introduction of the new and innovative Accula SARS-CoV-2 Test that delivers gold-standard reverse transcription-polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format.

    The Accula SARS-CoV-2 Test has received Emergency Use Authorization (EUA) from the United States (U.S.) Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.

    “Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,” said Amit Chopra, Managing Director, India, and South Asia, Thermo Fisher Scientific. “Thermo Fisher’s new testing platform combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 Test is a natural extension to our existing offerings and will significantly help to meet the continuing demands for rapid and reliable COVID-19 testing in India.”

    RT-PCR testing is streamlined from start to finish using a fully integrated, single-use microfluidic test cassette and the reusable, palm-sized Accula Dock. The test uses nasal swab samples and provides reliable, qualitative results in approximately 30 minutes. The Accula SARS-CoV-2 Test is enabled by proprietary PCR technology that allows for reduced absolute temperatures and reduced temperature differentials—resulting in rapid exponential amplification while reducing overall thermocycling times.

    “The rapid Accula point-of-care test will open new avenues of personal and public testing without compromising on accuracy,” added Amit. “The introduction of the test in India is a demonstration of the impact our solutions have on human health during the pandemic, and far beyond.”

    In January 2021, Thermo Fisher acquired Mesa Biotech Inc., which developed the Accula SARS-CoV-2 Test to provide accurate and faster results at the point of care.

    For more information, please visit www.thermofisher.com

    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

    Healthcare
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Continued vigilance is essential to protect India’s polio-free status

    November 17, 2026

    Apollo Health strengthens its expansion in North India with New Clinic and National Reference Laboratory in Gurugram

    November 16, 2026

    Aayush Wellness Launches Himalayan Shilajit Drops as Global Shilajit Market is Projected to Reach USD 436.72 Million by 2034, Growing at 8.67% CAGR

    November 16, 2026

    Comments are closed.

    Recent Post
    • Neetu Yoshi Reports 4.0% YoY Growth in Net Profit in H1 FY27 to Rs 12.00 Crore; Total Income Stands at Rs 59.38 Crore
    • Global Schools Group Opens Applications for Fully Funded Global Citizen Scholarship 2027
    • Raise Money Ventures Lights Up Noida’s Startup Ecosystem with a Festive Diwali Networking Celebration
    • After the Success Of His memoir ‘One Fine Day’, Author Sameer Bhide Embarks On His Second Book
    • Global Schools Group Opens Applications for its fully-funded Global Citizen Scholarship 2027
    • The 110th Anniversary Celebration of Baptist Church Karol Bagh Trust
    • The Quiet Rewiring of the Customer Conversation
    • HKL Global Movement Hoists Flags of 116 Nations at International Conference in Punjab

    Type above and press Enter to search. Press Esc to cancel.